LC-MS Profiling of Nucleotide Pools
The Degradation Problem
| Analyte | Stability at room temperature | Degradation route |
|---|---|---|
| ATP | Minutes | Phosphatase hydrolysis to ADP, AMP, adenosine |
| ADP, AMP | Minutes | Continued hydrolysis |
| dNTP | Minutes | Hydrolysis; also cell-cycle dependent |
| NAD⁺ | Minutes to hours | Glycohydrolase; pH dependent |
| GTP, CTP, UTP | Minutes | Hydrolysis |
Important distinction. The degradation products are themselves nucleotides in the panel. A slow extraction therefore does not merely lower the values — it redistributes them, converting ATP into ADP and AMP and changing the energy charge it appears to measure. The artefact is systematic and it mimics a biological state.
Part 1 — Quench and Extract
| Step | Recommendation | Why |
|---|---|---|
| Medium removal | Rapid aspiration, or direct quench on the plate | Washing takes time; cells continue metabolising |
| Quench | Ice-cold 0.5–1 M perchloric acid, or cold 80% methanol with 0.1 M formic acid | Stops enzyme activity immediately |
| Time from medium removal to quench | Under 30 seconds | The dominant determinant of the result |
| Extraction | Ice, sonication or freeze–thaw cycles | Complete release from cells |
| Neutralisation | Ammonium bicarbonate or potassium hydroxide, on ice | Perchloric acid must be removed before LC-MS |
| Centrifugation | 4 °C, to remove protein and salt | Precipitate interferes with injection |
| Injection | Immediately, or store at −80 °C | Storage changes the profile |
The third row is the single most important operational variable in this protocol. Two laboratories with identical chromatography and different harvest times will report different energy charges from the same cells.
Part 2 — Chromatography
| Approach | Suits | Note |
|---|---|---|
| Ion-pairing reverse phase (e.g. tributylamine, HFBA) | NTP, dNTP, sugar nucleotides | Excellent separation; ion-pair reagent contaminates the instrument |
| HILIC | Nucleotides, some cofactors | Good for polar analytes; peak shape sensitive to pH |
| Porous graphitic carbon | Nucleotides | Robust; long equilibration |
| Reverse phase with derivatisation | Selected analytes | More work; better specificity for some |
Readout note. Nucleotides are small, highly charged and chemically similar, so separation rather than detection is the limiting step. A method that resolves ATP from dATP, or GDP from dGDP, is what allows the deoxy and ribo pools to be reported separately; without that resolution, the two are one peak.
Part 3 — Normalisation
| Basis | Appropriate when | Caveat |
|---|---|---|
| Cell number | Proliferation is not the variable | Counting accuracy at low cell numbers |
| Total protein | Routine | Protein changes with treatment |
| Cell volume | Comparing concentrations | Volume measurement is indirect |
| Internal standard (isotope-labelled ATP) | Absolute quantification | Corrects recovery, not degradation before quench |
| Total phosphate or total metabolite sum | Metabolomics-style comparisons | Assumes the sum is stable |
Important distinction. An isotope-labelled internal standard added at the extraction step corrects for losses during processing, but it does not correct for degradation that occurred before the standard was added. That is why the quench time matters more than the standard.
Part 4 — What the Profile Can Support
| Claim | Requires | Not sufficient |
|---|---|---|
| "ATP fell" | Quenched, calibrated measurement with recovery | A relative fold-change from a slow extraction |
| "dNTP pool fell" | Separate dNTP measurement | Total nucleotide or ATP |
| "Synthesis increased" | Labelled precursor incorporation | Pool size |
| "Energy charge changed" | ATP, ADP and AMP measured together | ATP alone |
| "Antimetabolite engaged its target" | Target metabolite change plus downstream effect | Drug response alone |
Part 5 — Common Failures
- • Harvest taking minutes, so the profile reports degradation.
- • Medium not removed, so extracellular nucleotides contaminate the measurement.
- • Washing with warm buffer, which allows metabolism to continue.
- • Perchloric acid not neutralised or removed, damaging the column and suppressing ionisation.
- • Reverse phase without ion-pairing, giving poor retention and peak shape.
- • Total nucleotide reported as dNTP.
- • Repeated freeze–thaw of extracts.
- • Normalisation to protein in treatments that change protein content.
- • No internal standard, so recovery is unknown.
Part 6 — Where This Article Connects
This is the analytical companion to the nucleotide metabolism article, which covers the routes and the antimetabolite logic. It connects to the one-carbon tracing article, since labelled formate and glycine are measured in the same nucleotide pool, and to the serine article, which supplies the glycine and formate.
If you need nucleotide pools measured with rapid quenching and dNTP resolution, we can scope the analysis with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Nucleotide pools, degradation rates and extraction recovery vary by cell type, matrix and method; recovery and quench time must be established for the specific protocol.
A pool size does not establish a synthesis rate, and ATP does not report the deoxyribonucleotide pools that limit replication.
Scientific interpretation and experimental design
- • Quench time dominates. Under 30 seconds.
- • Degradation redistributes, not only lowers.
- • Remove medium first. Extracellular nucleotides contaminate.
- • Internal standard corrects processing, not pre-quench loss.
- • Resolve deoxy from ribo. They are different pools.
- • ATP is not dNTP.
Selected references for further reading
- • Lane AN, et al. Rapid and reliable quantitation of amino acids and nucleotides by LC-MS/MS. Journal of Chromatography B. 2019;1125:121713.
- • Lu W, et al. Analytical strategies for LC-MS-based targeted metabolomics. Journal of Chromatography B. 2008;871:236–242.
- • Bennett BD, et al. Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli. Nature Chemical Biology. 2009;5:593–599.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »